| Revenue growth | FY26 revenue up 20.43% YoY to ₹280.67 crore. |
|---|---|
| Margins | EBITDA margin up 164 bps to 20.25%, masking 40% diagnostic margins. |
| Order book | Five PPP projects secured, estimated at ₹800 crore over 10 years. |
| Demand visibility | Strong, driven by pan-India expansion and multi-state PPP projects. |
| Management confidence | Extremely optimistic, emphasizing aggressive geographical expansion and scalable platforms. |
Growth
FY26 revenue grew 20.4% to ₹280.67cr; B2B segment surged an impressive 50% year-on-year.
Outlook
Targeting 1,000 operational franchises within 24 months and 40% diagnostic EBITDA margins once centers mature.
Risks
High receivables from government projects (up to 6 months) and heavy expansion capex pressure overall margins.
Earnings Call filed with NSE, NSE: CHANDAN. Summary written with AI assistance from the document.
Chandan Healthcare Ltd: key numbers
- Share price
- ₹241.05
- Market cap
- ₹619.5 Cr
- Revenue (annual)
- ₹276.4 Cr
- Net profit (annual)
- ₹28.55 Cr
- P/E (TTM)
- 21.7×Sector 53.1×
- Promoter holding
- 49.61%+0.06% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chandan Healthcare Ltd
All →Chandan Healthcare Capacity Expansion
Chandan Healthcare scaled its diagnostic franchise network to 500+ centres, reaching a total of 568+ centres. It targets 1,000 centres by FY27-end and 3,000 in two years.
- diagnostic franchise collection centres
- 500 franchise centres
Chandan Healthcare Results Correction
Chandan Healthcare clarified to NSE it has one reportable segment, explaining the omission of segment-wise details in its Q4 FY27 financial results.
Chandan Healthcare Capital Structure Change
Chandan Healthcare Limited has allotted 5,99,998 equity shares upon conversion of fully convertible warrants, aggregating to ₹14.04 Crore.
- Value
- ₹14.04 Cr
Chandan Healthcare Board Meeting Outcome
Chandan Healthcare Ltd's board approved the appointment of an Independent Director, ratified cost auditor remuneration, and recommended varying the objects for utilising unutilised warrant proceeds.
Chandan Healthcare Annual General Meeting
Chandan Healthcare Limited announced the EGM voting results held on 29 August 2026. Shareholders approved the disinvestment of its entire shareholding in Chandan Pharmacy Limited.
Chandan Healthcare Annual General Meeting
Chandan Healthcare Limited held an EGM to approve the disinvestment of its entire stake in subsidiary Chandan Pharmacy Limited for approximately ₹16.77 Crore. This strategic divestment focuses resources on core diagnostics.
- Value
- ₹16.77 Cr